Natco Pharma gains on US FDA nod for $1.4bn Lynparza generic
Natco Pharma's stock climbed 5% after securing a tentative US regulatory nod for a generic version of AstraZeneca's Lynparza, though patent litigation continues to cloud the timeline for market entry.
Natco Pharma shares rose 5% on Monday after the US Food and Drug Administration granted tentative approval for its Olaparib tablets. The Indian drugmaker's 100 mg and 150 mg doses were found bioequivalent to AstraZeneca's branded drug, Lynparza. This regulatory step allows Natco to prepare for a potential launch, though it stops short of final market clearance.
The development highlights a significant revenue prospect for the company. Industry data indicates that Olaparib tablets generated approximately $1.4 billion in US sales over the 12 months ending in March 2026. To capture a share of this market, Natco will manufacture the tablets while Alembic Pharmaceuticals will handle the commercialisation and distribution across the US.
Investors, however, cannot yet count on this income. Natco explicitly warned that its Para IV patent litigation remains ongoing. Until this legal dispute with the patent holder is resolved, the tentative approval cannot convert into a final green light, leaving the exact timing of the US launch uncertain.
The FDA update arrives amid a broader effort by Natco to diversify its international presence. On July 14, the company completed an acquisition of an additional 13.25% stake in Adcock Ingram Holdings, positioning itself more deeply within South Africa's pharmaceutical and healthcare sector.
From a market perspective, Natco's equity still reflects substantial caution. Despite touching an intraday high of Rs 987.55 on Monday, the stock remains well below its 52-week high of Rs 1,226.80. It has also climbed significantly from its 52-week low of Rs 789.
Valuation metrics suggest the market is not pricing in a guaranteed Lynparza windfall. Natco currently trades at a price-to-earnings ratio of 11.93 and a price-to-book ratio of 1.83, which are modest compared to many pharmaceutical peers. Technical indicators show a 14-day Relative Strength Index of 47.6, signalling neutral momentum rather than aggressive buying.
Institutional positioning during the June 2026 quarter revealed a split in sentiment. Foreign institutional investors reduced their holdings to 16.99% from 17.37%. Conversely, domestic mutual funds increased their stake to 1.92% from 1.72%, pointing to selective accumulation by local institutions.
